Cytokinetics Inc Equity-NMS: CYTK

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$33.23

Open :

$33.39

Today's high :

$34.91

Today's low :

$33.17

52W low :

$29.31

52W high :

$59.39

EPS(TTM): :

-5.12

Shares O/S :

119.66 M

Market cap :

4.11 B

What is the share price of Cytokinetics Inc today?

Cytokinetics Inc (CYTK) share price as of January 1, 1970, is $. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Cytokinetics Inc?

Yes, Indian Investors can invest in the Cytokinetics Inc (CYTK) Share by opening an international trading account with Angel One.

How can I purchase Cytokinetics Inc shares in India?

Purchasing Cytokinetics Inc (CYTK) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Cytokinetics Inc (CYTK) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Cytokinetics Inc?

Yes, you can purchase fractional shares of Cytokinetics Inc (CYTK) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Cytokinetics Inc?

The market capitalization of Cytokinetics Inc on January 1, 1970, is $0.

What documents are required to invest in Cytokinetics Inc stocks?

In order to invest in Cytokinetics Inc (CYTK) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.